🇺🇸 FDA
Patent

US 11365246

Anti CCL24 (EOTAXIN2) antibodies for use in the treatment of hepatic diseases

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 11365246 (Anti CCL24 (EOTAXIN2) antibodies for use in the treatment of hepatic diseases) held by CHEMOMAB LTD. expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CHEMOMAB LTD.
Grant date
Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K45/06, A61P